Genden Biotechnology (Shanghai) Co., Ltd.

Genden Biotechnology (Shanghai) Co., Ltd. is a technology-intensive innovative enterprise based on modern medicine and life sciences. Relying on China's future blue ocean of the big health industry and standing at the forefront of the national health sector, the company is committed to becoming China's premier unicorn enterprise in comprehensive life health management by strategically deploying the R&D and transformation of regenerative medicine technology and life health medical services. Genden Biotechnology's business scope covers cell preparation and storage, iPS cell and immune cell research and application transformation, and it applies cutting-edge technologies to facilitate the translation of fundamental research achievements in cell technology into clinical practice and applications. In 2018, Dr. Kondo Yasushi, a core member of the research team of Nobel Prize laureate in Physiology or Medicine, Professor Shinya Yamanaka, and his scientific research team joined Genden Biotechnology. Meanwhile, Genden Biotechnology co-established a regenerative medicine laboratory with the Tenth People's Hospital affiliated to Tongji University, jointly built the first biological cell center in Northeast China with Northeast International Hospital, and established close cooperative relationships with numerous international cutting-edge medical research institutions, including the Japanese Institute of Biological Therapy and the TRT Group. Currently, the company is at a leading level in the field of regenerative medicine, especially in iPS cell research and transformation. Genden Biotechnology owns two subsidiaries, Shanghai Zhiquan Biotechnology Co., Ltd. and Genden Health Management (Shanghai) Co., Ltd., and is creating a new pattern of the regenerative medicine industry by laying out regional cell technology centers and regional health management centers to build a nationwide network of regional life centers. Shanghai Zhiquan Biotechnology Co., Ltd. is a high-tech R&D company based on cell preparation and storage, clinical research and application transformation of iPS cells and immune cells. It plans to use advanced iPS cell technology to carry out translational research in disease modeling and pathogenesis, new drug screening, and cell replacement therapy, aiming to provide strong support for meeting the needs of treating major diseases and improving the health level of the Chinese people, as well as promoting national major scientific research strategies and the development of the regenerative medicine industry. Genden Health Management (Shanghai) Co., Ltd. is a comprehensive life management service company integrating lifestyle intervention, precision cell medicine, and life-cycle management services. With high-quality health and medical resources at home and abroad, an excellent marketing service system, and a mature core management team, it focuses on providing systematic solutions for national health, disease prevention, and rehabilitation based on its comprehensive life health management system, enabling infinite possibilities for life. Genden International Outpatient Clinic is China's first integrated medical institution heavily invested by Genden Biotechnology (Shanghai) Co., Ltd. It is located on the 4th floor of the Medical Technology Center of Shanghai New Hongqiao International Medical Park, covering an area of 2,000 square meters. The clinic has ten departments, with well-known experts at home and abroad providing diagnosis and treatment services, combined with a cutting-edge medical system integrating Japanese preventive medicine, clinical medicine, rehabilitation medicine, functional medicine, and cell medicine.